3-(2,4-dimethoxybenzylidene)anabaseine has been researched along with Schizophrenia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchanan, RW; Christians, U; Freedman, R; Harris, J; Johnson, L; Kem, WR; Olincy, A; Wagner, BD | 1 |
| Buchanan, RW; Freedman, R; Kem, WR; Lewis, AS; Olincy, A; Picciotto, MR | 1 |
| Bourin, C; Bristow, LJ; Easton, A; Jones, KM; McDonald, IM; Olson, RE | 1 |
| Freedman, R | 1 |
| Hashimoto, K | 1 |
| Legget, KT; Smucny, J; Tregellas, JR; Wylie, KP | 1 |
| Arias, HR; Hołuj, M; Kos, T; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Buccafusco, JJ; Terry, AV | 1 |
| Du, YP; Freedman, R; Johnson, L; Kem, WR; Martin, LF; Olincy, A; Shatti, S; Singel, D; Soti, F; Tanabe, J; Tregellas, JR | 1 |
| Freedman, R; Johnson, L; Kem, WR; Leonard, S; Martin, LF; Olincy, A; Rojas, DC; Shatti, S; Soti, F; Tanabe, J; Tregellas, JR | 1 |
| Cannon, CE; Eddins, D; Egbertson, MS; Puri, V; Uslaner, JM; Vivian, JA | 1 |
| Kem, WR; O'Neill, HC; Rieger, K; Stevens, KE | 1 |
| Freedman, R; Kem, WR; Martin, LF | 1 |
| Adler, LE; Allensworth, D; Ellis, J; Freedman, R; Harris, JG; Johnson, LL; Kem, WR; Kongs, S; Leonard, S; Martin, L; Olincy, A; Pender, V; Soti, F; Stevens, JO; Stevens, KE; Zerbe, GO | 1 |
| Olincy, A; Stevens, KE | 1 |
| Allensworth, D; Ball, MP; Buchanan, RW; Clement, B; Freedman, R; Gold, JM; Guzman-Bonilla, A; Harris, JG; Johnson, L; Kem, WR; Kutnick, J; Martin, LF; Olincy, A; Pender, V; Soti, F; Stevens, KE; Wagner, BD; Zerbe, GO | 1 |
5 review(s) available for 3-(2,4-dimethoxybenzylidene)anabaseine and Schizophrenia
| Article | Year |
|---|---|
α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Attention; Benzylidene Compounds; Cognition; Eye Movements; Fetal Development; Humans; Memory; Nicotine; Nicotinic Agonists; Pyridines; Schizophrenia; Sensory Gating; Smoking | 2014 |
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Benzylidene Compounds; Biomarkers; Evoked Potentials, Auditory; Humans; Pyridines; Quinuclidines; Schizophrenia; Sensory Gating; Thiadiazoles | 2015 |
Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Biomarkers; Cholinergic Agents; Humans; Magnetic Resonance Imaging; Neuroimaging; Pyridines; Schizophrenia | 2016 |
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzylidene Compounds; Chromosomes, Human, Pair 15; Clozapine; Evoked Potentials, Auditory; Humans; Neural Inhibition; Nicotinic Agonists; Polymorphism, Single Nucleotide; Pyridines; Receptors, Nicotinic; Schizophrenia; Sensation Disorders | 2004 |
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Evoked Potentials, Auditory; Humans; Learning; Male; Memory; Mice; Nicotinic Agonists; Pyridines; Receptors, Nicotinic; Schizophrenia | 2007 |
5 trial(s) available for 3-(2,4-dimethoxybenzylidene)anabaseine and Schizophrenia
| Article | Year |
|---|---|
Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Topics: Adolescent; Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Archaeal Proteins; Benzylidene Compounds; Cognition; Cognition Disorders; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Pyridines; Schizophrenia; Schizophrenic Psychology; Young Adult | 2018 |
Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.
Topics: Adult; Benzylidene Compounds; Brain; Brain Mapping; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Nicotinic Agonists; Oxygen; Pyridines; Schizophrenia | 2010 |
Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Benzylidene Compounds; Brain; Brain Mapping; Cognition Disorders; Dose-Response Relationship, Drug; Eye Movements; Female; Genotype; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Nicotinic Agonists; Polymorphism, Single Nucleotide; Pyridines; Receptors, Nicotinic; Schizophrenia | 2011 |
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Topics: Adult; Benzylidene Compounds; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Evoked Potentials, Auditory; Female; Humans; Male; Neuropsychological Tests; Nicotinic Agonists; Placebos; Psychiatric Status Rating Scales; Pyridines; Receptors, Nicotinic; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2006 |
Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Topics: Adult; Attention; Benzylidene Compounds; Brief Psychiatric Rating Scale; Cognition Disorders; Drug Administration Schedule; Female; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Nicotinic Agonists; Pyridines; Receptors, Cholinergic; Receptors, Nicotinic; Schizophrenia; Severity of Illness Index | 2008 |
6 other study(ies) available for 3-(2,4-dimethoxybenzylidene)anabaseine and Schizophrenia
| Article | Year |
|---|---|
Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia.
Topics: Benzylidene Compounds; Humans; Nicotinic Agonists; Psychiatric Status Rating Scales; Pyridines; Schizophrenia; Schizophrenic Psychology | 2018 |
Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Attention; Benzamides; Benzylidene Compounds; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clozapine; Cognition Disorders; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Discovery; Male; Maze Learning; Neuropsychological Tests; Pyridines; Rats; Rats, Sprague-Dawley; Schizophrenia; Set, Psychology | 2014 |
3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Topics: Acrylamides; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Attention; Benzylidene Compounds; Cognition; Disease Models, Animal; Furans; Ketamine; Male; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Social Behavior | 2017 |
A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.
Topics: Animals; Antipsychotic Agents; Benzylidene Compounds; Cognition Disorders; Conditioning, Operant; Cotinine; Female; Hallucinogens; Ketamine; Macaca nemestrina; Male; Memory; Nicotinic Agonists; Pyridines; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Schizophrenic Psychology | 2009 |
The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Behavior, Animal; Benzylidene Compounds; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Donepezil; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Indans; Ketamine; Macaca mulatta; Male; Molecular Targeted Therapy; Nicotinic Agonists; Nootropic Agents; Piperidines; Psychomotor Performance; Pyridines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Schizophrenia | 2013 |
DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.
Topics: Animals; Auditory Diseases, Central; Benzylidene Compounds; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Electroencephalography; Evoked Potentials, Auditory; Male; Nicotinic Agonists; Pyridines; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Isolation; Time Factors | 2003 |